Biogen is going back to its roots, changing the company’s name after being known as Biogen Idec since 2003. The change reflects the focus of the company now vs. when it merged with Idec in 2003.

The company disclosed the change early Monday and unveiled a new logo as well as a new sign at its campuses in RTP.

Its local operations focus on small and large scale biologics manufacturing, a patient services operation and an oral solid dosage manufacturing facility. It employs more than 1,300 workers in the Triangle, adding more than 100 employees in recent months.

Biogen (Nasdaq: BIIB) says the change won’t have any impact on local operations.

“While our name and logo will be different, our longstanding commitment to North Carolina and the Triangle community will not change,” said Joydeep Ganguly, vice president and general manager of the Research Triangle Park operations for Biogen, in a statement. “It is truly an exciting time for our company. Yet, despite these changes, our mission remains the same. We continue to be a company determined to bring forward important new medicines in areas of unmet medical need.”

According to the comapny, Biogen now focuses on neurology, immunology and hematology. The Idec deal in 2003 was focused on oncology products.

“It is an exciting time for our company, and our new brand identity is a reflection of both our past and our future potential contributions,” said George Scangos, chief executive officer of Biogen. “We have created a truly differentiated organization by focusing on patients, excellent science and world-class execution. Now, as we enter new therapeutic areas and new markets, we have the opportunity to clarify and simplify our message for those who rely on us.”